Clinical Trials
3 trialsNCT07011654 2026-05-20
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT01757626 2026-01-07
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT06026657 2025-07-08
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting